Carcinoma, Non-Small Cell Lung Clinical Trials

7 recruiting

Carcinoma, Non-Small Cell Lung Trials at a Glance

7 actively recruiting trials for carcinoma, non-small cell lung are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Houston, Lexington, and Chicago. Lead sponsors running carcinoma, non-small cell lung studies include AstraZeneca, Genprex, Inc., and Georgetown University.

Browse carcinoma, non-small cell lung trials by phase

Treatments under study

About Carcinoma, Non-Small Cell Lung Clinical Trials

Looking for clinical trials for Carcinoma, Non-Small Cell Lung? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Non-Small Cell Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Non-Small Cell Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell Lung
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled294 locationsNCT06868277
Recruiting
Phase 1Phase 2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Carcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled32 locationsNCT07227298
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 2

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Georgetown University18 enrolled4 locationsNCT04499053
Recruiting
Phase 1Phase 2

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Carcinoma, Non-Small Cell Lung
Genprex, Inc.158 enrolled10 locationsNCT04486833
Recruiting
Phase 3

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Carcinoma, Non-Small Cell Lung
AstraZeneca280 enrolled105 locationsNCT06008093